Papers
9
Total Citations
205
H-Index
8
About
Ashkan Mortezavi is a leading urologic surgeon and researcher whose work focuses on advancing surgical outcomes for prostate and bladder cancer, particularly through the refinement of robotic-assisted techniques. His major contributions center on evaluating the safety, efficacy, and oncological outcomes of robot-assisted radical cystectomy (RARC) and radical prostatectomy (RARP). Notably, his 2022 study in *JAMA Network Open*—cited 34 times—challenged long-standing assumptions by showing that RARC with intracorporeal urinary diversion was associated with lower mortality and better perioperative outcomes than open surgery, a finding with significant implications for bladder cancer care. Mortezavi has also pioneered research on focal therapy for prostate cancer, including a prospective multicenter study on high-intensity focused ultrasound (HIFU) that reported safety outcomes (42 citations), and has explored salvage prostatectomy after HIFU failure. His work on positive surgical margins, lymph node dissection, and perioperative management (e.g., continuous aspirin therapy) has helped refine surgical standards. With multiple papers in high-impact journals and active leadership in the European Association of Urology Robotic Urology Section, Mortezavi’s research is shaping the future of minimally invasive urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9